Cargando…
Development of a topical liposomal formulation of Amphotericin B for the treatment of cutaneous leishmaniasis
BACKGROUND: Currently, there is no topical treatment available for any form of cutaneous leishmaniasis (CL) in most of the endemic areas. The aim of the current study was to develop a topical nano-liposomal Amphotericin B (AmB) for the treatment of CL. METHODOLOGY/PRINCIPAL FINDINGS: Liposomes conta...
Autores principales: | Jaafari, Mahmoud Reza, Hatamipour, Mahdi, Alavizadeh, Seyedeh Hoda, Abbasi, Azam, Saberi, Zahra, Rafati, Sima, Taslimi, Yasaman, Mohammadi, Akram Miramin, Khamesipour, Ali |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6904837/ https://www.ncbi.nlm.nih.gov/pubmed/31582344 http://dx.doi.org/10.1016/j.ijpddr.2019.09.004 |
Ejemplares similares
-
Novel and safe single-dose treatment of cutaneous leishmaniasis with implantable amphotericin B-loaded microparticles
por: Sousa-Batista, Ariane J., et al.
Publicado: (2019) -
Route map for the discovery and pre-clinical development of new drugs and treatments for cutaneous leishmaniasis
por: Caridha, Diana, et al.
Publicado: (2019) -
Novel benzoxaborole, nitroimidazole and aminopyrazoles with activity against experimental cutaneous leishmaniasis
por: Van Bocxlaer, Katrien, et al.
Publicado: (2019) -
In-situ immune profile of polymorphic vs. macular Indian Post Kala-azar dermal leishmaniasis
por: Sengupta, Ritika, et al.
Publicado: (2019) -
Successful treatment by adding thalidomide to meglumine antimoniate in a case of refractory anthroponotic mucocutaneous leishmaniasis
por: Goyonlo, Vahid Mashayekhi, et al.
Publicado: (2019)